Tofacitinib in paediatric dermatoses: a narrative review.

Ishan Agarwal, Maitreyee Panda, Anupam Das

Clinical and experimental dermatology 2022 Jul

filter terms:

Tofacitinib has revolutionized the treatment of numerous dermatological conditions in different age groups. However, evidence for its effectiveness, safety and tolerability in the paediatric population is limited. We performed a literature search, which showed that oral tofacitinib is a reliable option in refractory juvenile dermatomyositis, severe alopecia areata, atopic dermatitis and psoriasis. Topical tofacitinib is an effective option in vitiligo and halo naevus. The risk-benefit ratio should be assessed prior to consideration of this molecule. In this narrative review, we have attempted to present a summary of the evidence of using tofacitinib (oral and topical) in paediatric dermatoses. © 2022 British Association of Dermatologists.

Citation

Ishan Agarwal, Maitreyee Panda, Anupam Das. Tofacitinib in paediatric dermatoses: a narrative review. Clinical and experimental dermatology. 2022 Jul;47(7):1256-1264